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Abstract
Background
Osteogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by
recurrent fractures. Although most cases of OI have heterozygous mutations in
COL1A1 or COL1A2 and show autosomal dominant inheritance, during the last
years there has been an explosion in the number of genes responsible for both
recessive and dominant forms of this condition. Herein, we have analyzed a
cohort of patients with OI, all offspring of unaffected parents, to determine the
spectrum of variants accounting for these cases. Twenty patients had nonrelated
parents and were sporadic, and 21 were born to consanguineous relationships.
Methods
Mutation analysis was performed using a next-generation sequencing gene
panel, homozygosity mapping, and whole exome sequencing (WES).
Results
Patients offspring of nonconsanguineous parents were mostly identified with
COL1A1 or COL1A2 heterozygous changes, although there were also a few cases
with IFITM5 and WNT1 heterozygous mutations. Only one sporadic patient
was a compound heterozygote for two recessive mutations. Patients offspring of
consanguineous parents showed homozygous changes in a variety of genes
including CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, TMEM38B, and
WNT1. In addition, two patients born to consanguineous parents were found
to have de novo COL1A1 heterozygous mutations demonstrating that causative
variants in the collagen I structural genes cannot be overlooked in affected chil-
dren from consanguineous couples. Further to this, WES analysis in probands
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lacking mutations in OI genes revealed deleterious variants in SCN9A, NTRK1,
and SLC2A2, which are associated with congenital indifference to pain (CIP)
and Fanconi–Bickel syndrome (FBS).
Conclusion
This work provides useful information for clinical and genetic diagnosis of OI
patients with no positive family history of this disease. Our data also indicate
that CIP and FBS are conditions to be considered in the differential diagnosis
of OI and suggest a positive role of SCN9A and NTRK1 in bone development.
Introduction
Osteogenesis imperfecta (OI; MIMs: 166200, 166210,
166220, 166230, 259420, 259440, 610682, 610915, 610967,
610968, 613848, 613849, 613982, 614856, 615066, 615220,
616229, 616507) is a genetically heterogeneous condition
characterized by fragile bones which are prone to fracture.
This disorder is one of the most frequent skeletal dys-
plasias with an estimated prevalence of 6-7/100,000 (Van
Dijk et al. 2010). Phenotypically, the severity of OI is
variable, extending from affected individuals with mild
symptoms to cases with a high number of fractures or
even neonatal lethality (Sillence et al. 1979). Additional
features commonly found in patients with OI are short
stature, bone deformities, wormian bones, dentinogenesis
imperfecta, blue sclera, hearing loss, and increased vascu-
lar fragility. Typically, OI is associated with defects in the
production of collagen type I and consistently 85–90% of
OI cases have heterozygous dominant mutations in either
COL1A1 (MIM: 120150) or COL1A2 (MIM: 120160)
encoding procollagen a1(I) and a2(I) peptide chains,
respectively (Chu et al. 1983; Byers and Steiner 1992; For-
lino and Marini 2016). Dominant variants in IFITM5
(MIM: 614757) and P4HB (MIM: 176790) have also been
described in a few affected individuals, with the latter
gene being mutated in the OI-like disorder named Cole-
Carpenter syndrome (MIM: 112240). P4HB codes for the
beta subunit of prolyl 4-hydroxylase, which is implicated
in procollagen prolyl hydroxylation and folding, and
IFITM5 is an osteoblast-specific gene associated with
matrix mineralization (Rauch et al. 2015; Forlino and
Marini 2016). OI is also transmitted as an autosomal
recessive trait in a minority of cases. Patients with autoso-
mal recessive OI (AR-OI) have been reported with muta-
tions in an increasingly growing collection of genes. Most
AR-OI genes, including BMP1 (MIM:112264), CRTAP
(MIM: 605497), FKBP10 (MIM: 607063), LEPRE1 (MIM:
610339), PLOD2 (MIM: 601865), PPIB (MIM:123841),
SEC24D (MIM: 607186), SERPINH1 (MIM: 600943), and
TMEM38B (MIM: 611236) are involved in procollagen (I)
post-translational modifications, processing, folding,
secretion, and cross-linking (Garbes et al. 2015; Forlino
and Marini 2016). However, there is also another group
of AR-OI loci, which are not recognized as directly impli-
cated in type I collagen biosynthesis, but play a role in
mineralization or osteoblast development. Among this
second group of genes are CREB3L1 (MIM: 616215),
SERPINF1 (MIM:172860), SP7 (MIM: 606633), SPARC,
(MIM: 182120), and WNT1 (MIM:164820) (Mendoza-
Londono et al. 2015; Forlino and Marini 2016). Lastly,
mutations in PLS3 (MIM: 300131) and more recently in
MBTPS2 (MIM: 300294) have been associated with two
distinct forms of X-linked OI (van Dijk et al. 2013; Lin-
dert et al. 2016).
In this work, we have analyzed 42 independent OI pro-
bands, all offspring of unaffected parents, to determine in
light of the recent advances in the molecular pathogenesis
of OI, the spectrum of mutated genes and variants
accounting for these cases. In addition, we have identified
pathogenic variants in SCN9A (MIM: 603415), NTRK1
(MIM: 191315), and SLC2A2 (MIM: 138160) in patients
with a clinical history compatible with OI.
Materials and Methods
NGS sequencing panel
DNA extracted from peripheral blood was subjected to
mutation screening using a customized next-generation
sequencing (NGS) gene panel containing 16 genes associ-
ated with OI (Appendix S1). This panel was designed
with Roche NimbleDesign software (https://design.nim-
blegen.com). For each sample, paired-end libraries were
created with the help of KAPA HTP Library Preparation
Kit for Illumina platforms (Kapa Biosystems, Boston,
MA, USA), SeqCap EZ Library SR (Roche Nimblegen,
Madison, WI, USA), and NEXTflex-96 Pre Capture
Combo Kit for indexing (Bioo Scientific, Austin, TX,
USA). Sequencing was conducted on a MiSeq system
(Illumina, San Diego, CA, USA) according to the manu-
facturer0s standard operating protocol. NGS variants were
filtered and those identified as pathogenic were subse-
quently confirmed by Sanger sequencing and subjected to
segregation analysis in the corresponding family.
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SNP arrays
Briefly, 200 ng of genomic DNA from peripheral blood
were used to conduct a genome-wide scan of 850,000
SNPs, using the Illumina CytoSNP-850k BeadChip fol-
lowing the manufacturer’s specifications (Illumina). Gen-
Call scores <0.15 at any locus were considered “no calls”.
Hybridization results were analyzed using Genome Studio
software (Illumina). Homozygous regions were identified
by evaluating allele frequency for all SNPs. Genomic posi-
tions were based on NCBI Build 37 (dbSNP version 130).
Candidate gene screening
For probands of consanguineous families, all coding exons
of candidate AR-OI genes in regions of homozygosity were
PCR amplified and sequenced by Sanger sequencing as pre-
viously described (Caparros-Martin et al. 2013). Regarding
cDNA analysis, total RNA was obtained from skin primary
fibroblasts using Tri Reagent Solution (ThermoFisher Scien-
tific, Waltham, MA, USA). Subsequently, five micrograms
of RNA were retrotranscribed with superscript II and ran-
dom primers (ThermoFisher Scientific) and used for PCR.
Mutation nomenclature
Mutations are named following the HGVs nomenclature
guidelines taking the A of the first ATG as nucleotide +1,
and checked with Mutalyzer (http://www.LOVD.nl/mut-
alyzer) (Wildeman et al. 2008). Variants were considered
novel when they were not present in the LOVD OI database
maintained by the University of Leicester (https://oi.-
gene.le.ac.uk) or in HGMD (http://www.hgmd.cf.ac.uk).
The following reference sequences were used: COL1A1:
NM_000088.3; COL1A2: NM_000089.3; CRTAP: NM_006371.4;
FKBP10: NM_021939.3; IFITM5: NM_001025295.2; LEPRE1:
NM_022356.3; PLOD2: NM_182943.2; PPIB: NM_000942.4;
SERPINF1: NM_002615.5 and NG_028180.1; TMEM38B:
NM_018112.2 and NG_032971.1; WNT1: NM_005430.3;
NTRK1: NM_002529.3; SCN9A: NM_002977.3; SLC2A2:
NM_000340.1.
Whole exome sequencing
Whole exome sequencing (WES) was provided by Sistemas
Genomicos S.L., Valencia, Spain Briefly, capture and
enrichment of DNA targeted regions were performed using
the SureSelect Human All Exon Target Enrichment kit for
51 Mb (Agilent Technologies) and exome libraries were
sequenced on a HiSeq2000 sequencing platform (Illu-
mina). Reads were aligned against the human reference
genome version GRCh37/hg19 and the filtering process
was conducted with Picard-tools (http://
picard.sourceforge.net/) and SAM-tools (Li et al. 2009). A
combination of two different algorithms VarScan (Koboldt
et al. 2009) and GATK (McKenna et al. 2010) was used
for variant calling and identified variants were annotated
using the Ensembl database [www.ensembl.org]. Candidate
variants were validated by Sanger sequencing.
In silico analysis of variants
Pathogenicity prediction was obtained using CADD V1.3
(http://cadd.gs.washington.edu) (Kircher et al. 2014),
SIFT, Polyphen, and MutationTaster, the last three avail-
able in Alamut V2.7 (Interactive Biosoftware, Rouen,
France). Splicing alterations were predicted using Splice-
siteFinder-like, MaxEntScan, NNSplice, Genesplicer, and
Human Splicing Finder, which are also available in Ala-
mut V2.7 (Interactive Biosoftware).
Results
Patients and mutation analysis
We studied 20 sporadic patients offspring of unrelated
parents and 22 probands offspring of consanguineous
parents, all with clinical diagnosis of OI. For all patients
both parents were confirmed to be unaffected. Patients
who had nonconsanguineous parents were screened using
a customized NGS gene panel containing previously
reported OI genes (NGS-OI). Affected individuals from
consanguineous families and their siblings were first sub-
jected to homozygosity mapping using SNP arrays, and
subsequently, all the AR-OI genes contained within candi-
date homozygous blocks larger than 1 MB were analyzed
by Sanger sequencing. For patient 1010, with lethal OI
type, both consanguineous parents were tested with the
NGS-OI-specific gene panel due to lack of proband mate-
rial. All mutations were verified by Sanger sequencing and
confirmed to segregate with the disease in the corre-
sponding family. Missense changes were subjected to in
silico pathogenicity analysis and ExAC population allele
frequencies were examined for all variants. Appropriate
informed consent was obtained from patients or patients’
guardians according to the declaration of Helsinki princi-
ples of medical research involving human subjects. This
study was approved by the CSIC Institutional Review
Board and the Medical Research Ethics Committee of the
Egyptian National Research Centre.
Mutations in sporadic cases offspring of
nonconsanguineous parents
We identified heterozygous mutations in COL1A1 or
COL1A2 in 12/20 sporadic patients of nonrelated parents.
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In six of them, DNA from both progenitors was available,
and the corresponding mutations were confirmed to have
arisen as de novo events. Three patients referred with
clinical suspect of OI-V had the recurrent c.-14C>T
IFITM5 mutation characteristic of this type of OI in the
heterozygous state and generated de novo (Cho et al.
2012; Semler et al. 2012), and a 35-year-old female
described with short stature, vertebral fractures, and
early-onset osteoporosis was found with a heterozygous
frameshift mutation in WNT1. The same mutation was
also detected in the heterozygous state in her mother who
only presented osteoporosis after menopause. Finally, one
patient was the result of a recessive trait due to com-
pound heterozygous mutations in SERPINF1 and no
mutations were detected in three cases (Table 1). In total,
six mutations were novel including two nucleotide dele-
tions in WNT1 and SERPINF1 and four glycine substitu-
tions affecting Gly-XY tripeptide repeats of the a1(I) or
a2(I) chains. Gly-XY repeats are the main component of
a-chains and the requirement of glycines every three
amino acids for collagen I triple helix formation has been
largely documented (Dalgleish 1997).
Mutations in patients offspring of
consanguineous parents
Affected individuals from consanguineous families were
identified with homozygous mutations in the following
OI recessive genes: SERPINF1 (four families), CRTAP
(three families), FKBP10 (two families), PLOD2 (two
families), TMEM38B (two families), WNT1 (two families),
LEPRE1 (one family), and PPIB (one family). No muta-
tions were detected in five cases, and 10 mutations were
novel (Table 2). Of the 10 unreported variants, four are
predicted to introduce a stop codon either directly or fol-
lowing a frameshift, one was a deep intronic splicing
mutation and five corresponded to amino acid substitu-
tions. Missense variants, in addition to not being detected
in ExAC, were subjected to in silico analysis which was
consistent with pathogenicity in all cases. Only two vari-
ants, p.Asp349Gly (c.1046A>G) and p.Met9Val in CRTAP
and PPIB, respectively, showed slightly lower pathogenic-
ity values. Nevertheless, the c.1046A>G variant, located
23 bp upstream of the 30end of CRTAP exon 5, was pre-
dicted by five different splice site recognition programs to
generate a novel donor splice site (Fig. S1). Likewise,
PPIB Met9, which is a conserved residue in vertebrates,
has been suggested to be in fact the start codon of PPIB,
as the protein encoded by this gene was not detected on
western blots or by immunofluorescence in fibroblasts
from a patient characterized with a Met9Arg homozygous
mutation (Barnes et al. 2010). Furthermore, two affected
siblings of proband 1011 were found to be homozygous
for the p.Met9Val variant, while the sequence of an unaf-
fected brother was normal.
Family 69 was identified with a deep intronic mutation
in SERPINF1. SNP arrays in the proband of this family
and her similarly affected sister were consistent with a
mutation in SERPINF1 as the two siblings shared a
9.1 Mb homozygous region on chromosome 17 encom-
passing this gene. Since no mutations were detected on
sequencing all SERPINF1 coding exons, we performed
RT-PCR in skin primary fibroblasts using primers cover-
ing the entire ORF of the gene. This produced a larger
PCR product in the proband with respect to a control,
which was found to contain a 63 bp in-frame insertion
between coding exons 5 and 6 by sequencing. Amplifica-
tion and sequencing of the corresponding genomic region
and flanking DNA revealed a homozygous G>A substitu-
tion (c.786+715G>A) in the two affected sisters, which
creates a novel consensus acceptor splice site
(CGG>CAG) that results in the activation of a pseu-
doexon from intron 5 (Fig. S2). The c.786+715G>A
mutation was absent from the 1000 Genome Database.
Disparity of phenotypes associated with
PLOD2 mutations
Egyptian families 91 and 1020 were linked to PLOD2 by
homozygosity mapping. This gene was contained within a
32 Mb homozygous block in the index patient of family
91 and within a region of homozygosity of 90 Mb shared
by the two affected siblings of family 1020. Sequencing of
PLOD2 in the proband of each family revealed a homozy-
gous donor splice site mutation in intron 12
(c.1358+5G>A) in the affected girl of family 91, previ-
ously reported by our group in another Egyptian patient
(Puig-Hervas et al. 2012), and a novel homozygous mis-
sense mutation, p.Trp610Arg, in the affected sisters of
family 1020. The new amino acid change involves a
highly conserved residue from exon 16 which is adjacent
to the exon 17 cluster of missense mutations (R619H,
G622V, G622C, V627A, T629I) associated with Bruck
syndrome 2 (BRKS2; MIM: 601865) (van der Slot et al.
2003; Ha-Vinh et al. 2004; Puig-Hervas et al. 2012; Zhou
et al. 2014). BRKS is a recessively inherited form of OI
that includes congenital contractures as a distinguishing
feature (McPherson and Clemens 1997) and is caused by
PLOD2 or FKBP10 mutations (Shaheen et al. 2010).
Notably, the patients from families 91 and 1020 showed
quite different phenotypes (Fig. S3). The proband from
family 91 is a 9-year-old girl with no congenital contrac-
tures. Her first fracture occurred at 6 years of age and
afterward there was an average of 1–2 fractures/year. She
had a short stature (height: 4.0 SD; weight: +0.4 SD;
head circumference: +0.3 SD), blue sclera, very mild
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hypotonia, wormian bones, and osteoporosis revealed by
DEXA (total body Z-score: 2.5 and forearm Z-score:
4.4). In contrast, the two sisters from family 1020 had a
very severe form of BRKS. Both, the proband (13 years
and 7 months old) and her younger sister (4 years and
8 months old) presented grayish blue sclera, congenital
joint contractures, bone deformities, kyphoscoliosis, and
muscle wasting of lower limbs. They were both under-
weight (4.3 and 3.3 SD, respectively), short (12.3
and 5.0 SD, respectively), and microcephalic (6.0 and
4.0 SD, respectively). Fractures started 3 days after birth
in the proband and at birth in the other sibling and
recurred with an average of 10 fractures per year with
severe bone pain. X-ray of upper and lower limbs in both
sisters revealed thin bowed serpentine long bones with
metaphyseal widening, honey comb appearance, and mul-
tiple fracture sites with callus formation. DEXA for the
proband demonstrated severe osteoporosis (spine Z-score:
5.5 SD). In addition to craniosynostosis and severe
developmental delay (SQ: 26 by Vineland Social Maturity
Scale), the younger sister had facial palsy since birth. 3D
skull scan CT revealed bilateral premature closure of
coronal and lambdoid sutures, closed posterior fontanelle,
preserved anterior fontanelle, prominent cortical sulci,
basal cistern, and dilatation of ventricular system.
Differential diagnosis of OI
Five of the 22 probands of consanguineous families
yielded a negative result for mutations in AR-OI genes.
These patients were either not linked to any of the
reported AR-OI loci by homozygosity mapping or were
detected with no mutations after sequencing the candi-
date genes embedded in the corresponding homozygous
regions. As this suggested the possibility of additional OI
genes, we performed WES in four of these patients (fami-
lies 16, 30, 84, 1007). The fifth proband was analyzed
with the NGS-OI panel (family 1009). Despite parental
consanguinity, the two affected children from families 30
and 1009 were found to have COL1A1 heterozygous
mutations which were demonstrated to be de novo fol-
lowing analysis of the corresponding sequence of their
progenitors (Table 3). WES data in the three other
remaining probands showed no pathogenic changes in
COL1A1/2 or any other OI genes, and consequently, this
prompted us to search for rare variants contained within
the candidate homozygous regions previously uncovered
by the SNP arrays. As a result, we identified a homozy-
gous nonsense mutation (p.Trp190*) in the voltage-gated
sodium channel encoded by SCN9A in the proband of
family 84 that was also in homozygosis in her affected
aunt, and a homozygous missense change involving a
conserved residue of the extracellular domain of theTa
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neurotrophic receptor tyrosine kinase 1, NTRK1
(p.Pro311Leu) in the index patient of family 16 (Fig. S4).
Remarkably, SCN9A is associated with congenital indiffer-
ence to pain (CIP; MIM: 243000) and NTRK1 with con-
genital insensitivity to pain with anhidrosis (CIPA, MIM:
256800) (Mardy et al. 1999; Cox et al. 2006). The third
proband, from family 1007, had a missense mutation in
SLC2A2 (p.Gly119Arg), affecting also a conserved amino
acid. SLC2A2 codes for a glucose transporter and is
mutated in Fanconi–Bickel syndrome (FBS; MIM:
227810) (Santer et al. 1997). The selected variants in
SCN9A, NTRK1, and SLC2A2 were not in the ExAC data-
base, were confirmed to segregate with the disease in the
three families and were estimated as pathogenic by the
four in silico programs we used for predicting pathogeni-
city (Table 3). To the best of our knowledge, they repre-
sent novel mutations. Subsequent re-evaluation of the
phenotype was consistent with the molecular findings
especially in patients from families 84 and 1007
(Appendix S1). The proband from family 16 had dry skin
and anhidrosis as occurs with CIPA patients having
NTRK1 mutations, but could still feel pain and superficial
sensations, which suggests that the p.Pro311Leu substitu-
tion is likely to act as a hypomorphic mutation
(Appendix S1for clinical descriptions and Fig. S4).
Discussion
Herein, we have characterized the mutation spectrum of
a large cohort of OI patients with no parental positive
history of this disease. The results of this study show that
sporadic patients from nonconsanguineous relationships
commonly have heterozygous COL1A1 or COL1A2 muta-
tions generated de novo, whereas mutations in other
dominant genes or compound heterozygous mutations in
recessive genes are rare in these cases. Sporadic patients
with OI type V represent an exception, since they consis-
tently have the c.-14C>T IFITM5 mutation typical of this
type of OI (Rauch et al. 2013). In a patient with a mild
phenotype, initially thought as sporadic, we found a new
dominant pathogenic variant in WNT1. Interestingly, the
mother of this patient carried the same mutation and
her only complaint was osteoporosis after menopause.
Thus, WNT1 mutant variants not only can result in
dominant or recessive inheritance [(Keupp et al. 2013)
and Tables 1 and 2], but can also show variable expres-
sivity. No mutations were detected in three sporadic
cases born to nonrelated parents following NGS-OI panel
testing. Although this could be an indication of addi-
tional unraveled causative OI genes for these cases, it
needs to be taken into account that deep intronic muta-
tions or dosage variations have not been addressed by
our screening methodology. Further studies in these threeTa
b
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patients including WES analysis in a trio manner (pro-
band and parents) are required to clarify the underlying
genetic defect in each of these patients. In consan-
guineous families, all the affected subjects were identified
with homozygous changes in recessive genes except for
two probands who to our surprise had de novo COL1A1
pathogenic variants. Thus, screening of COL1A1 and
COL1A2 is recommended also in consanguineous fami-
lies. Concerning AR-OI genes, our study has confirmed
in additional patients, that mutations in PLOD2 are asso-
ciated with phenotypes of variable severity ranging from
mild OI to very severe BRKS. This has previously been
reported only once, most likely due to the low rate of
PLOD2 mutations (Puig-Hervas et al. 2012). The PLOD2
homozygous change (c.1358+5G>A) detected in the pro-
band of family 91 was previously reported by our group
in another independent Egyptian patient of consan-
guineous parents (Puig-Hervas et al. 2012). In this report,
the c.1358+5G>A variant was subjected to minigene analy-
sis and in this system, no production of wild-type product
was observed, indicating that it is likely to be a fully pene-
trant mutation (Puig-Hervas et al. 2012). Comparing the
phenotype of the two patients with the same PLOD2 muta-
tion, both have no contractures and white sclera, but differ
in the severity of the condition. The patient reported in
Puig-Hervas et al. 2012 had more than 10 fractures per year
and kyphoscoliosis with a clinical severity score (CSS) of 16
(severe) (Aglan et al. 2012). In contrast, the patient of this
study presented 1–2 fractures per year and mild kyphosis,
with a CSS of 10 (moderate severity). Further to this, the
proband of family 91 was identified with myopathy evi-
denced by electromyogram and muscle biopsy histochem-
istry also revealed selective type 2 atrophy as a nonspecific
myopathic feature. This finding was not observed in the
patient reported earlier with the same mutation. Because
exome sequencing was not performed in proband 91, the
myopathy of this patient could result from another variant
in a different gene. However, it should be noted that abnor-
malities in muscle fibers in addition to bone fragility have
been described in a recently developed plod2 mutant zebra-
fish, and thus there is also the possibility of the muscle dys-
function of this patient being part of the phenotypic
spectrum associated with mutations in PLOD2 (Gistelinck
et al. 2016).
In family 1020, one of the affected sisters also identified
with a PLOD2 mutation, had in addition to bone fragility
and congenital contractures, an unusual association of
craniosynostosis and microcephaly with intellectual dis-
ability. Since this is not a typical feature of BRKS and
because of the parental consanguinity, we are inclined to
think that this is likely to be due to a different associated
condition for which we cannot figure out a definite
syndrome.
Our data also suggest that mutations in SERPINF1
might be the most frequent finding among families with
recessive inheritance. In agreement with this, while this
manuscript was under review, a study of 598 OI individu-
als was published in which SERPINF1 followed by CRTAP
were also identified as the genes more frequently mutated
in AR-OI (Bardai et al. 2016). Nevertheless, this has to be
confirmed by further studies.
Three patients from two independent consanguineous
families with clinical features suggestive of OI proved to
have mutations in SCN9A (two patients) and NRTK1
(one patient) which are associated with CIP, and an addi-
tional patient had a missense change in the FBS gene
SLC2A2. Hence, these two conditions should be consid-
ered in the differential diagnosis of OI, especially during
the first years of life when other distinctive clinical signs
of CIP or FBS are not evident. CIP patients are often
reported with recurrent bone fractures (Schulman et al.
2001; Perez-Lopez et al. 2015; Phatarakijnirund et al.
2016), and although this could be explained as a conse-
quence of the absence of pain perception, it could also be
indicative of a possible role of the nociceptive neurons in
bone homeostasis. The NTRK1 patient from this study is
pointing to the latest as this girl was found to have osteo-
porosis by DEXA (Appendix S1); however, further DEXA
studies of CIP patients are required to be able to draw a
reliable conclusion. How nociceptive fibers could influ-
ence the biology of bone is largely unknown, although
there exists the possibility that they could regulate bone
remodeling. Relative to this, blockage of Cav2.2 channels
in nociceptors was shown to induce the osteoclast activa-
tor RANKL in a preclinical joint inflammation model
generated in mice (Baddack et al. 2015). The connection
between SLC2A2 and bone fragility is much clear since
hypophosphatemia and rickets are key clinical features of
FBS and low phosphate levels result in deficient bone
mineralization. The inactivation of the SLC2A2 glucose
transporter impairs renal tubular reabsorption of phos-
phate due to proximal renal tubular dysfunction sec-
ondary to glycogen accumulation. Differential diagnosis
of OI has been previously hinted in FBS patients by Hadi-
pour et al. 2013, who reported a 3.5 year girl presenting
with recurrent bone fractures and atypical clinical presen-
tation that was initially diagnosed as OI, but whose cor-
rect diagnosis as FBS was confirmed by molecular studies
(Hadipour et al. 2013). There are also other reports indi-
cating that wide phenotypic variability adds difficulty for
accurate diagnosis of such rare disorder. For example,
atypical or mild presentation with absent hepatomegaly
and short stature in two sisters was described by Grunert
et al. 2012. Our patient at presentation had features of
nutritional rickets which improved with treatment. On
follow up, he showed short stature, growth retardation,
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mild hepatomegaly, fasting hypoglycemia but no gluco-
suria nor aminoaciduria. He also had multiple fractures,
wormian bones, and severe osteoporosis in DEXA, which
are typical characteristics of OI, thus making it difficult
to reach a definite diagnosis by clinical assessment only.
Similarly, the patient with NTRK1 mutation had on one
hand repeated fractures and osteoporotic features, and on
the other anhidrosis, but could feel pain and superficial
sensations. Our results emphasize the importance of
molecular data to confirm the diagnosis and help in
proper counseling and management. Particularly, in
developing countries with limited access to advanced
molecular studies, close and regular follow-up of patients
with recurrent fractures is of utmost importance to check
for other emerging symptoms and signs that appear with
time and can change the diagnosis.
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